AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Dec. 8, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET / 10:35 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com/. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Michael York, Senior Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web Site: http://www.amylin.com/

Copyright